Defender’s plans for motion sickness nasal gel stop with FDA rejection

31 Jan 2024
www.pharmaceutical-technology.com
Phase 3Phase 2NDAClinical ResultDrug Approval
Defender’s plans for motion sickness nasal gel stop with FDA rejection
Preview
Source: Pharmaceutical Technology
Nasa is helping with Defender’s development of DPI-386, as astronauts are particularly susceptible to motion sickness in space. Image credit: Shutterstock/Supamotionstock.com.
The FDA has decided to not approve Defender Pharmaceuticals’ intranasal scopolamine candidate for motion sickness, issuing a complete response letter (CRL) to the US-based company.
Defender’s drug, known as DPI-386, is indicated for the prevention of nausea and vomiting induced by motion in adults.
Defender’s CEO Barry I Feinberg said the company plans on scheduling a formal meeting with the FDA to discuss the issues raised and to create a plan going forward, in a 30 January press release.
DPI-386 is a nasal gel version of the antimuscarinic drug scopolamine, first approved by the FDA as a transdermal patch in 1979, according to the drug’s label. Currently, patches are placed behind the ear and work with high efficacy by depressing the parasympathetic nervous system.
The gel could be particularly useful for astronauts and military personnel who are frequently exposed to motion. Nasa joined forces with Epiomed Therapeutics to develop a fast-acting nasal spray version of scopolamine in 2012. According to the St Louis Post-Dispatch, Defender purchased Epiomed in 2014 and was founded the same year. Headquartered in St Louis, Missouri, the company has also worked with the United States Naval Medical Research Unit.
See Also:Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status
Defender’s plans for motion sickness nasal gel stop with FDA rejection
Preview
Source: Pharmaceutical Technology
Revolo advances plans to tackle eosinophilic esophagitis with orphan drug tag
Defender’s plans for motion sickness nasal gel stop with FDA rejection
Preview
Source: Pharmaceutical Technology
Defender’s formulation aims for rapid absorption to induce quicker onset. In a Phase III trial more than 500 participants, who usually get motion sick, had improved symptoms after being exposed to open sea conditions while using DPI-386. Subjects who received the nasal gel demonstrated lower incidences of vomiting and fewer requests for rescue medication compared to a placebo group. The incidence of moderate to severe nausea was also lower.
In a September 2023 statement announcing the new drug application (NDA) acceptance, Defender said results from five phase III trials were submitted as evidence. The NDA was assigned priority review status by the FDA at the request of the US Navy.
Feinberg added: “We remain confident that our intranasal scopolamine is a safe and effective therapy for the prevention of motion sickness, and we will work closely with the FDA to ensure that we can bring this innovative new product to the market.”
Defender is also exploring the use of DPI-386 in major depressive disorder (MDD) with suicide ideation, chemical exposure accidents, and virtual reality sickness.
In October 2023, Defender announced further collaborations with Nasa to study DPI-386 in Phase II trials to mitigate G-transition-induced motion sickness and enhance sensorimotor performance.
Scopolamine recently made the news beyond the healthcare sector after rising incidences of it being linked to criminal activity. In June 2023, the US Embassy in Colombia highlighted the sedative side effects of the drug are being increasingly used to target tourists in the country.  In certain doses, the drug can cause unconsciousness for 24 hours or more.
Scopolamine was also the first drug to infamously garner the “truth serum” tag.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.